- Home
- LEV vs PLX Comparison
LEV vs PLX Comparison
Compare LEV & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LEV
- PLX
- Stock Information
- Founded
- LEV 2011
- PLX 1993
- Country
- LEV Canada
- PLX Israel
- Employees
- LEV N/A
- PLX N/A
- Industry
- LEV Auto Manufacturing
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LEV Consumer Discretionary
- PLX Health Care
- Exchange
- LEV Nasdaq
- PLX Nasdaq
- Market Cap
- LEV 76.0M
- PLX 79.4M
- IPO Year
- LEV N/A
- PLX 1998
- Fundamental
- Price
- LEV $0.21
- PLX $1.71
- Analyst Decision
- LEV Buy
- PLX
- Analyst Count
- LEV 4
- PLX 0
- Target Price
- LEV $1.15
- PLX N/A
- AVG Volume (30 Days)
- LEV 919.1K
- PLX 439.0K
- Earning Date
- LEV 11-06-2024
- PLX 11-14-2024
- Dividend Yield
- LEV N/A
- PLX N/A
- EPS Growth
- LEV N/A
- PLX N/A
- EPS
- LEV N/A
- PLX N/A
- Revenue
- LEV $176,812,259.00
- PLX $45,667,000.00
- Revenue This Year
- LEV N/A
- PLX N/A
- Revenue Next Year
- LEV $68.85
- PLX $88.94
- P/E Ratio
- LEV N/A
- PLX N/A
- Revenue Growth
- LEV N/A
- PLX N/A
- 52 Week Low
- LEV $0.18
- PLX $0.82
- 52 Week High
- LEV $1.99
- PLX $1.90
- Technical
- Relative Strength Index (RSI)
- LEV 22.89
- PLX 75.47
- Support Level
- LEV $0.32
- PLX $1.60
- Resistance Level
- LEV $0.62
- PLX $1.75
- Average True Range (ATR)
- LEV 0.05
- PLX 0.11
- MACD
- LEV -0.02
- PLX 0.05
- Stochastic Oscillator
- LEV 9.99
- PLX 91.95
About LEV The Lion Electric Company
The Lion Electric Co. includes designing, developing, manufacturing and distributing purpose-built all-electric medium and heavy-duty urban vehicles including battery systems, chassis, bus bodies and truck cabins. The Group also distributes truck and bus parts and accessories. The Group has one reportable operating segment, the manufacturing and sales of electric vehicles in Canada and in the United States. Geographically, the majority of revenue is generated from Canada.
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.